Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 231

Livongo gives $100m IPO a go

Health management app developer Livongo Health was valued at $800m as of 2018, and a range of corporate investors could exit in the offering.

Jul 2, 2019

ConnectM moves into Keen Home

ConnectM Technology has acquired the smart vent maker for an undisclosed sum in a deal that handed an exit to NYU Innovation Fund.

Jul 2, 2019

Health Catalyst puts IPO plans in motion

UPMC and Kaiser Permanente are both in line for exits after health data platform developer Health Catalyst filed for a $100m initial public offering.

Jul 1, 2019

Karuna kicks its way into public markets

PureTech Health-backed neuropsychiatric drug developer Karuna Therapeutics raised $89.2m in an upsized offering that followed $123m in venture capital.

Jul 1, 2019

Illuminate Education coaches FastBridge Learning

FastBridge Learning spun out of University of Minnesota in 2015 and has been picked up by edtech firm Illuminate Education.

Jul 1, 2019

BridgeBio crosses over to public markets with $349m

AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.

Jun 28, 2019

Morphic shapes $90m initial public offering

Morphic began trading on the Nasdaq Global Market yesterday after issuing 6 million shares priced at $15 each, providing exits to AbbVie, GSK, Novo, Pfizer, Schrödinger and ShangPharma.

Jun 28, 2019

Adaptive Biotechnologies shapes $300m IPO

Shares in Adaptive Biotechnologies, backed by Microsoft, Celgene, Illumina, LabCorp and BD Biosciences, soared more than 100% on its first day of trading.

Jun 28, 2019

The RealReal realises IPO plans in $300m offering

Novel Group-backed luxury goods marketplace The RealReal will raise $300m in an initial public offering in which it will float above its range.

Jun 28, 2019

Morphic shapes $90m initial public offering

Morphic began trading on the Nasdaq Global Market yesterday after issuing 6 million shares priced at $15 each, providing exits to AbbVie, GSK, Novo, Pfizer, Schrödinger and ShangPharma.

Jun 28, 2019
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here